Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Techniclone (TCLN) -- Ignore unavailable to you. Want to Upgrade?

To: EZLibra who wrote (2834)	1/6/1999 10:12:00 AM
From: shero	Respond to of 3702

Happy new year, Davis, and all. To answer your question if you were a pharmaceutical company you would prefer to treat for the rest of life. Obviously the patient would choose the opposite. I think this might be one test of Bymaster. His statement about VTA being ready in 12-18 months is EXACTLY what Lon said at the time of the Peregrine acquisiton, circa 1997.

To: EZLibra who wrote (2834)	1/6/1999 12:59:00 PM
From: Tim K	Read Replies (1) \| Respond to of 3702

Welcome back to the board Davis. I read the company's release to determine if the patent covers just Techniclone's VTA technology, or all vascular targeting agents being developed by Techniclone and by any other companies, even if the receptors are diferent. It doesn't clearly state that it covers other companies vascular targeting technology, but will cover delivery of other companies' chemo., or other agents using Thecniclone's VTA. With your statement "The patent covers anything which targets the receptor and its' ligands, a ligand being a hormone, signal, or any other label. Everything past, present and future used to kill a tumor by destroying the vasculature is covered." you indicate it does cover other companies. Did you read this into the news release or obtain it elsewhere? I hope you're right!